PATENT CLAIM ANALYSIS

Application Number: 15940133
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "235200"]

Abstract:
Described herein are quinoline compounds useful for, among other things, inhibition of the proteasome and for treatment of cancer and inflammation.

Claim (Index 3):
The compound of  claim 1 , which is a compound of the formula IV: wherein: the dashed line represents a single or a double bond; R 6  is hydrogen, alkyl or aryl; R 8  is hydrogen, halogen, or alkyl; R 10  is hydrogen, halogen, alkyl, or alkoxy; and R 11  and R 12  are each, independently, hydrogen or alkyl or, R 11  and R 12 , together with the nitrogen atom to which they are attached, form a heterocyclyl group optionally containing one additional heteroatom.

Metadata:
- Claim Count in Document: 24.0
- Percentile: 90.0
- Lexical Diversity: 1.2
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12950764', '13262888', '14658736', '14431935', '13821195']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7612973856304291
- 35 USC 102 Novelty (BERT): 0.492664967178499
- Combined Prediction Score: 0.7344341437852361
- Mean Citation Score: 195.95137800000003
- Max Citation Score: 197.04544
- Similarity Product: 134.81901636642456

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test